An acid and GSH dual-controlled nanoplatform enhances cancer treatment by using triptolide to regulate NRF2 and inhibit GSH protein expression, reducing GPX4 activity and promoting ferroptosis, while minimizing toxicity [999]. The gene discussed is NFE2L2; the disease is cancer.